6 completed, 1 active not recruiting, 1 approved for marketing, 1 unknown. 6 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 2 | Completed 2 |
Follow margetuximab: new trials by email Literature Review of margetuximab trials Research Report on margetuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer Margetuximab, Tucatinib, Capecitabine - Metastatic Breast Cancer, Advanced Breast Cancer | Phase 2 | Withdrawn | MedSIR | 2022-05-15 | 2022-07-11 | |
| MARGetuximab Or Trastuzumab (MARGOT) Paclitaxel, Pertuzumab, Margetuximab - Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 174 | 2020-07-13 | 2025-11-18 |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine) - Breast Cancer Metastatic | Phase 2 | Unknown | Zai Lab (Shanghai) Co., Ltd. | 123 | 2020-01-13 | 2023-08-22 |
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer margetuximab, Retifanlimab, Tebotelimab - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 / Phase 3 | Completed | MacroGenics | 82 | 2019-09-30 | 2025-06-08 |
| A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg - Advanced Solid Tumors, Hematologic Neoplasms | Phase 1 | Completed | MacroGenics | 277 | 2017-08-18 | 2023-12-21 |
| Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer Margetuximab 10 mg/kg, Margetuximab 15 mg, Pembrolizumab - Gastric Cancer, Stomach Cancer | Phase 1 / Phase 2 | Completed | MacroGenics | 95 | 2016-01-01 | 2025-03-17 |
| Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Margetuximab, Trastuzumab, Physician's choice of chemotherapy. - HER-2 Positive Breast Cancer, Metastatic Neoplasm | Phase 3 | Completed | MacroGenics | 624 | 2015-08-24 | 2025-03-17 |
| Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer Margetuximab - Breast Cancer | Phase 2 | Completed | MacroGenics | 25 | 2013-03-01 | 2025-03-13 |
| Safety Study of MGAH22 in HER2-positive Carcinomas margetuximab - Breast Cancer, Gastric Cancer | Phase 1 | Completed | MacroGenics | 66 | 2010-07-01 | 2025-02-26 |
| Margetuximab Expanded Access Program Margetuximab - HER2-positive Breast Cancer, HER2-positive Carcinoma | Approved for marketing | TerSera Therapeutics LLC | 2025-02-14 |
Breast Neoplasms (4) · Stomach Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Esophageal Neoplasms (1) · Hematologic Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Recurrence (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
MacroGenics (6) · Dana-Farber Cancer Institute (1) · MedSIR (1) · TerSera Therapeutics LLC (1) · Zai Lab (Shanghai) Co., Ltd. (1)
United States (7) · South Korea (4) · Poland (3) · Taiwan (3) · Canada (2) · Germany (2) · Italy (2) · Singapore (2) · Spain (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Bulgaria (1) · China (1)
Adrienne Waks, MD (1) · Ashley Ward, MD (1) · Stephen L. Eck, MD, PhD (1)
PMID 28119295, PMID 32653053, PMID 33263418, PMID 33480963, PMID 36332179, PMID 37104758, PMID 37857711, PMID 38751523, PMID 41811823